These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1805 related articles for article (PubMed ID: 31835042)

  • 61. Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice.
    Garinet S; Lupo A; Denize T; Loyaux R; Timsit S; Gazeau B; Fabre E; Maaradji Z; Gibault L; Giroux-Leprieur E; Duchemann B; Monnet I; Jouveshomme S; Aldea M; Besse B; Le Pimpec-Barthes F; Leroy K; Wislez M; Blons H
    Pathology; 2024 Aug; 56(5):702-709. PubMed ID: 38834439
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Next-Generation Sequencing Approach to Non-Small Cell Lung Carcinoma Yields More Actionable Alterations.
    Mehrad M; Roy S; Bittar HT; Dacic S
    Arch Pathol Lab Med; 2018 Mar; 142(3):353-357. PubMed ID: 29219616
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable
    Szpechcinski A; Moes-Sosnowska J; Skronska P; Lechowicz U; Pelc M; Szolkowska M; Rudzinski P; Wojda E; Maszkowska-Kopij K; Langfort R; Orlowski T; Sliwinski P; Polaczek M; Chorostowska-Wynimko J
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063150
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
    Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
    Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
    Wei XW; Gao X; Zhang XC; Yang JJ; Chen ZH; Wu YL; Zhou Q
    Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971
    [TBL] [Abstract][Full Text] [Related]  

  • 66. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
    Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
    Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
    Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
    J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.
    Seker-Cin H; Tay TKY; Kazdal D; Kluck K; Ball M; Neumann O; Winter H; Herth F; Heußel CP; Savai R; Schirmacher P; Thomas M; Budczies J; Allgäuer M; Christopoulos P; Stenzinger A; Volckmar AL
    Lung Cancer; 2023 Oct; 184():107317. PubMed ID: 37586177
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
    J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
    Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065
    [TBL] [Abstract][Full Text] [Related]  

  • 71.
    Palacio S; Pontes L; Prado E; Arshad J; Ali R; Piha T; Bacchi CE; Mudad R; Lopes G
    Oncologist; 2019 Apr; 24(4):e137-e141. PubMed ID: 30446583
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
    Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
    Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tumor molecular profiling of NSCLC patients using next generation sequencing.
    Tsoulos N; Papadopoulou E; Metaxa-Mariatou V; Tsaousis G; Efstathiadou C; Tounta G; Scapeti A; Bourkoula E; Zarogoulidis P; Pentheroudakis G; Kakolyris S; Boukovinas I; Papakotoulas P; Athanasiadis E; Floros T; Koumarianou A; Barbounis V; Dinischiotu A; Nasioulas G
    Oncol Rep; 2017 Dec; 38(6):3419-3429. PubMed ID: 29130105
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 75. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
    Riely GL
    J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib.
    Onozawa H; Saito H; Sunami K; Kubo T; Yamamoto N; Kasajima R; Ohtsu T; Hiroshima Y; Kanamori H; Yokose T; Miyagi Y
    Thorac Cancer; 2020 Dec; 11(12):3599-3604. PubMed ID: 33034420
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
    Tang Y; Che N; Yu Y; Gao Y; Shi H; Feng Q; Wei B; Ma L; Gao M; Ma J; Lin D
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):407-416. PubMed ID: 31696302
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    Benjamin DJ; Haslam A; Gill J; Prasad V
    Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
    Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas.
    Lin LH; Allison DHR; Feng Y; Jour G; Park K; Zhou F; Moreira AL; Shen G; Feng X; Sabari J; Velcheti V; Snuderl M; Cotzia P
    Mod Pathol; 2021 Dec; 34(12):2168-2174. PubMed ID: 34362997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 91.